ClinicalTrials.gg
RecruitingNCT05457829Updated May 18, 2026

Doxorubicin Hydrochloride Liposome Combined With Irinotecan (AI Regimen) Versus VIT Regimen in the Treatment of Relapsed and Refractory Pediatric Rhabdomyosarcoma: a Prospective, Open-label, Randomized Controlled, Multicenter, Phase II Clinical Study

A Phase 2 interventional study of Doxorubicin Hydrochloride Liposome+Irinotecan and Temozolomide+Irinotecan+Vincristine in Rhabdomyosarcoma, Child, sponsored by Sun Yat-sen University. Recruiting at 1 site in China. Open to participants aged 6 Months to 18 Years. Per ClinicalTrials.gov, last updated 2026-05-18.

Sponsored by Sun Yat-sen University · Phase 2, Interventional, and Treatment

How we know

From the registry’s dates

  • Primary completion was expected by Jun 2026, 4 months ago, but the record still lists the study as recruiting.
  • Started Dec 2023; still recruiting 2 years 10 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
88
Allocation
Randomized
Ages
6 Months to 18 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 14 studies testing irinotecan in Rhabdomyosarcoma — 4 open to participants now, 6 under way, none of them phase 3. Irinotecan · Rhabdomyosarcoma.

Planned enrollment
8th of 14
88 · median 102
Started
2023
the only one that year
Phase 2
8 of 14
2 open now
Registered
13th of 14
by date
Lead sponsor
1 of 14
Sun Yat-sen University

Among the 14 studies testing irinotecan in Rhabdomyosarcoma, this one is the 8th largest by planned enrollment, is the only one that started in 2023, is one of 8 in phase 2, and was the 13th registered.

Rhabdomyosarcoma

238 studies on the registry are indexed under Rhabdomyosarcoma; 49 are open to participants now.

Browse Rhabdomyosarcoma studies →

Open to participants now

4 of the 14 studies testing irinotecan in Rhabdomyosarcoma are open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

About irinotecan

Irinotecan: first FDA approval 1996 (CAMPTOSAR), first EMA approval 2016. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 39 Rhabdomyosarcoma studies recruiting now, 8 (21%) set no upper age limit and 31 (79%) stop at 75 or younger; 35 take children under 18; none take healthy volunteers.

This study: 6 Months to 18 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 14 studies testing irinotecan in Rhabdomyosarcoma, or all of them as a file.
02

Study summary

This multicenter, randomized, controlled, open-label, prospective clinical trial was designed to evaluate the efficacy and safety of doxorubicin hydrochloride liposome injection in combination with irinotican (AI regimen) versus VIT regimen in the treatment of relapsed and refractory pediatric rhabdomyosarcoma.

Read the detailed description

The primary objective of this study was to evaluate the objective response rate (ORR) of relapsed and refractory rhabdomyosarcoma in children after 2 cycles of chemotherapy with AI or VIT regimens. Secondary objectives were to evaluate the disease control rate (DCR), progression-free survival (PFS), overall survival (OS), and safety of AI and VIT regimen in the treatment of relapsed and refractory pediatric rhabdomyosarcoma.

03

Conditions studied

  • Rhabdomyosarcoma, Child

Browse trials for

Keywords

  • Rhabdomyosarcoma
  • Doxorubicin Hydrochloride Liposome Injection
  • Irinotecan
04

Who can participate

Ages eligible
6 Months to 18 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. 6 months ≤age≤18 years, no gender limitation;
  2. The (≥16 years old) or Lansky (\< 16 years old) physical status score is at least 50;
  3. The expected survival time is not less than 12 weeks;
  4. Heart function: A) Cardiac COLOR ultrasound detection ≥ 50%; B) suggests no myocardial ischemia;C) No history of arrhythmia requiring drug intervention before enrollment;
  5. Patients who meet the clinical diagnostic criteria and are diagnosed with pediatric rhabdomyosarcoma;
  6. Patients who have progressed, after treatment (failed to achieve complete or partial response after recent treatment);
  7. (according to 1.1 standards, CT scan length of tumor lesions ≥10mm, CT scan short diameter of lymph node lesions ≥15mm, measurable lesions have not received radiotherapy, freezing and other local treatments);
  8. The patient must fully recover from the acute toxic effects of all previous anticancer chemotherapy: A) Myelosuppressive chemotherapy: at least 21 days after the last myelosuppressive chemotherapy (42 days if nitrosourea was used previously);B) Experimental drug or anticancer therapy other than chemotherapy: not available within the first 28 days of planned initiation of AI or VIT. Complete recovery from toxicity of the therapy must be determined;C) Hematopoietic growth factor: at least 14 days after the last administration of long-acting growth factor or 3 days after the last administration of short-acting growth factor;D) Immunotherapy: at least 42 days after completion of any type of immunotherapy (except ), such as and tumor vaccines; E) X-ray therapy (XRT) : at least 14 days after local palliative XRT (small mouth); For other substantial bone marrow (BM) irradiation, it must be completed for at least 42 days; F) Stem cell infusion without total body irradiation (TBI) : there is no evidence of active and the transplant or stem cell infusion must be completed at least 56 days after the infusion;
  9. Laboratory tests during screening should meet the following conditions: A) Absolute value of neutrophils (ANC) ≥1.5×109/L (if bone marrow invasion, ≥1.0×109/L); B) count (PLT) ≥75×109/L (PLT≥50×109/L for bone marrow invasion); C) (sum of combined + uncombined) ≤ 2.5× value (ULN) (corresponding to age), patients with confirmed Gilbert's syndrome can be included in the group according to the investigator's judgment; D) Estimated ≥30 mL/min/1.73 m2 or serum creatinine (Cr) ≤ 1.5ULN (calculated according to the standard formula); E) (AST) and alanine aminotransferase (ALT) ≤ 2.5×ULN (5 times ULN if liver is present)
  10. Able to comply with outpatient treatment, laboratory monitoring and necessary clinical visits during the study period;
  11. The parent/guardian of the child or adolescent subject is capable of understanding, agreeing to, and signing the study (ICF) and the applicable child consent form prior to initiating any program-related procedures; Subject is capable of expressing consent with parental/guardian consent (if applicable).

Exclusion criteria

Exclusion criteria

  1. Patients who had previously received irinotecan combined with temozolomide and vincristine, or who had progressed after treatment with irinotecan or temozolomide, or who had previously received doxorubicin hydrochloride liposome injection chemotherapy;
  2. Patients with central nervous system ;
  3. P450 enzyme-induced anticonvulsants (anticonvulsants affect irinotecan clearance);
  4. Previous or concurrent clinical significance of active cardiovascular diseases, including congenital heart disease or pericardial disease, history of heart failure, myocardial infarction, coronary heart disease, heart valvular disease, cardiomyopathy, arrhythmias (including persistent atrial fibrillation, complete left bundle branch block, frequent ventricular premature onset); Or prolonged (QTc) after current corrected heart rate > 480 ms; Patients with grade III \~ IV cardiac insufficiency according to the (NYHA) cardiac function classification (age > 3 years) or infant cardiac function standard (age ≤3 years), or (LVEF) \< 50% as indicated by color doppler echocardiography;
  5. Severe chronic skin diseases in the past;
  6. Previous allergic asthma or severe allergic disease;
  7. Poorly controlled hypertension and diabetes;
  8. Have a history of other tumors, except cured cervical cancer or basal cell carcinoma of the skin;
  9. surface antigen positive patients;
  10. or syphilis infected patients;
  11. Patients who have previously received organ transplants;
  12. Uncontrolled and active systemic bacterial, viral or fungal infection;
  13. to the use of large doses of hormones, such as uncontrolled hyperglycemia, gastric ulcers or mental diseases;
  14. Patients who had used doxorubicin at a cumulative dose of ≥450 mg/m2, or epirubicin at a cumulative dose of ≥ 550 mg/m2, or who had used anthracyclines in the past to induce heart disease;
  15. Have a history of severe neurological or psychiatric disorders, including epilepsy or autism.
Terms in these criteria, in plain language(24)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Karnofsky performance status (KPS)

A 0–100 scale of how well someone can carry out everyday activities. 100 is no complaints and no signs of illness; 70 is able to look after yourself but not to work or keep up normal activity; 50 is needing considerable help and frequent medical care.

Studies often ask for 60 or 70 and above. Your doctor gives the score.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

GVHD (graft-versus-host disease)

After a transplant from a donor, the donor’s immune cells attack the recipient’s body, often the skin, gut or liver.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
88 participants (estimated)

Study arms

  • Experimental
    AI Regimen

    Doxorubicin hydrochloride liposome injection combined with Irinotecan

    Drug: Doxorubicin Hydrochloride Liposome+Irinotecan

  • Active comparator
    VIT Regimen

    Temozolomide combined with Irinotecan and Vincristine

    Drug: Temozolomide+Irinotecan+Vincristine

Interventions

06

What researchers measure

Primary outcomes

  1. Objective response rate (ORR)

    Objective response rate (ORR) after 2 cycles of chemotherapy with AI or VIT regimen, including complete response (CR) and partial response (PR)

    Time frame: up to 2 cycles of chemotherapy(each cycle is 21 days)

Secondary outcomes

  1. Disease control rate (DCR)

    Refers to the percentage of patients with confirmed complete response, partial response, and disease stability in patients with evaluable efficacy.

    Time frame: up to 2 cycles of chemotherapy

  2. Progression-free survival (PFS)

    Means from the date of enrollment to the date of first disease progression or death from any cause, whichever comes first. If the subject has no disease progression during the trial period, PFS is defined as the last date until the subject's last confirmed progression-free survival.

    Time frame: From date of radomization unit the date of first documented progression or date of death from any cause, whichever came first, assessed up to 36 moths

  3. Overall survival (OS)

    Overall survival (OS) was defined from the date of enrollment to the date of death from any cause.

    Time frame: From date of radomization unit the date of first documented date of death from any cause, assessed up to 36 moths

  4. Adverse events (AE)

    The safety of the drug was evaluated by NCI-CTC AE 5.0 standard.

    Time frame: Time from the date of enrollment to 30 days after the last dose.

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Dec 2023 (actual). Primary completion is estimated for Jun 2026, 30 months after the start.

Of 36 non-industry phase 2 interventional studies under Rhabdomyosarcoma, half reached primary completion within 70 months of starting (the median), counting those still running; a quarter within 41 and three quarters within 94. This study's planned 30 months is below that.

Counting every sponsor, half of 39 studies reached it within 63 months; a quarter within 40 and three quarters within 92.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 7, 2022
First posted
Jul 14, 2022
StartActual
Dec 30, 2023
Primary completionEst.
Jun 30, 2026
CompletionEst.
Jul 31, 2026
Last update
May 18, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 18, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05457829
Responsible party
Yizhuo Zhang (Director of department of pediatric cancer,Principal Investigator,Clinical Professor, Sun Yat-sen University) — Principal investigator
First posted
Jul 14, 2022
Start date
Dec 30, 2023
Primary completion
Jun 30, 2026 (estimated)
Completion
Jul 31, 2026 (estimated)
Last update
May 18, 2026

Study contacts

Yzhuo Zhang, PhD
Contact
zhangyzh@sysucc.org.cn
020-87342460
Juan Wang
Contact
wangjuan@sysucc.org.cn
02087343598
Yizhuo Zhang, PhD
principal investigator · Sun Yat-sen University

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Liposomal doxorubicin · Irinotecan

Start the discussion